IDEXX reported strong Q4 2025 results with double-digit revenue growth, solid EPS expansion, and operating margin improvement led by Companion Animal Group diagnostics and record instrument placements.

IDEXX Laboratories posted a robust Q3 2025, achieving double-digit growth in revenue, earnings, and operating income, driven by strong performance in CAG Diagnostics and significant placements of inVue Dx instruments.

IDEXX delivered robust financial results in Q2 2025, driven by strong growth in Companion Animal Group diagnostics and record instrument placements. EPS rose 49% as reported, while international growth outpaced domestic gains.

IDEXX Laboratories delivered revenue of $998M and EPS of $2.96 in Q1 2025, supported by strong growth in VetLab consumables and software services, and boosted by the launch of a new cancer diagnostic panel.

IDEXX Laboratories announced its fourth-quarter results, with revenue reaching $954 million, a 6% increase year-over-year. Earnings per diluted share were $2.62, up 13% as reported and 10% on a comparable basis. The company's growth was supported by the Companion Animal Group and benefits from IDEXX's execution drivers.

IDEXX Laboratories reported a 7% increase in revenue for Q3 2024, reaching $976 million, with EPS at $2.80, an 11% increase. The growth was primarily driven by the Companion Animal Group (CAG) and Water segments. The company is updating its full year revenue growth guidance range to $3,865 million - $3,890 million.

IDEXX reported a 6% increase in revenue to $1,004 million in the second quarter of 2024. EPS decreased by 9% to $2.44, impacted by a litigation expense. The company is updating its full year revenue growth guidance range to $3,885 million to $3,945 million.

IDEXX Laboratories reported a 7% increase in revenue for Q1 2024, reaching $964 million. EPS increased by 10% to $2.81. The company is updating its full year revenue growth outlook range to 6.5% - 8.5% as reported and 7% - 9% organic.

IDEXX Laboratories, Inc. announced strong fourth-quarter results, with revenue reaching $902 million, a 9% increase compared to the prior year. Earnings per diluted share were $2.32, up by 13% as reported. The growth was primarily driven by the Companion Animal Group, with recurring revenue gains of 11% in CAG Diagnostics.

IDEXX Laboratories reported a 9% increase in revenue and an 18% increase in EPS for the third quarter of 2023. The growth was driven by strong performance in the Companion Animal Group (CAG) and Water segments. The company has updated its full-year revenue and EPS outlook.

IDEXX Laboratories reported a strong second quarter, with revenue reaching $944 million, a 10% increase both reported and organically. Earnings per share (EPS) grew by 71% to $2.67. The company has updated its 2023 revenue guidance to $3,660 million - $3,715 million and increased its EPS outlook to $9.64 - $9.90.

IDEXX Laboratories reported first-quarter revenue of $900 million, an 8% increase, with EPS of $2.55, a 12% increase. The results were driven by Companion Animal Group diagnostics recurring revenue growth and supported by a $16 million customer contract resolution payment.

IDEXX Laboratories reported a 3% increase in revenue for the fourth quarter of 2022, with solid organic revenue gains across its CAG, Water, and LPD business segments. The company's EPS was $2.05, an 8% increase, supported by operating margin expansion.

IDEXX Laboratories reported a 4% increase in revenue and a 6% increase in EPS for the third quarter of 2022. The growth was driven by a strong performance in the Companion Animal Group (CAG) Diagnostics, which saw a 5% increase in recurring revenue. Record premium instrument placements also contributed to the positive results.

IDEXX Laboratories reported a 4% increase in revenue to $861 million in the second quarter of 2022. EPS was $1.56, a 33% decrease, impacted by discrete R&D investments. The company has adjusted its 2022 revenue growth guidance to 3% - 5.5% and EPS outlook to $7.77 - $8.05.

IDEXX Laboratories reported an 8% increase in revenue to $837 million for Q1 2022, driven by CAG Diagnostics. EPS was $2.27, a 3% decline as reported. The company adjusted its 2022 guidance to reflect moderated veterinary clinical visit growth levels impacted by constraints on clinic capacity, strengthening of the U.S. dollar, and advancement of incremental discrete investments in future innovations

IDEXX Laboratories reported strong fourth-quarter results with revenue of $801 million, an 11% increase year-over-year. The growth was driven by a 13% increase in CAG Diagnostics recurring revenue. EPS was $1.89, a decrease of 6% as reported, but an increase of 12% on a comparable basis.

IDEXX Laboratories reported a strong third quarter, with revenue reaching $810 million, a 12% increase as reported and 10% organically. EPS grew to $2.03, a 20% increase. The results were driven by continued momentum in the Companion Animal Group (CAG) business.

IDEXX Laboratories reported Q2 2021 revenues of $826 million, a 30% increase, with EPS of $2.34, a 36% increase. The company also increased its 2021 revenue and EPS guidance.

IDEXX Laboratories reported a strong first quarter with a 24% increase in revenue and 82% increase in EPS. The growth was driven by strong performance in the Companion Animal Group (CAG) Diagnostics, as well as growth in the Livestock, Poultry and Dairy (LPD) business.

IDEXX Laboratories announced strong Q4 and full year 2020 results, driven by high growth in Companion Animal Group (CAG) Diagnostics recurring revenue and sustained growth in the Livestock, Poultry and Dairy (LPD) business. Q4 revenue increased by 19% and EPS increased by 93%.

IDEXX Laboratories reported Q3 2020 revenues of $722 million, a 19% increase. EPS was $1.69, representing 36% growth. The results were driven by Companion Animal Group Diagnostics recurring revenue growth.

IDEXX Laboratories reported a 3% increase in revenue, reaching $638 million for the second quarter of 2020. This growth was primarily driven by a 7% increase in Companion Animal Group (CAG) Diagnostics recurring revenue. The company's EPS was $1.72, a 20% increase, reflecting revenue growth and cost control benefits.

IDEXX Laboratories announced first quarter results with a 9% increase in revenue, reaching $626 million, driven by a 10% growth in Companion Animal Group (CAG) Diagnostics recurring revenue. EPS was reported at $1.29, a 10% increase. The company has withdrawn its 2020 guidance due to COVID-19 uncertainties.

IDEXX Laboratories reported a 10% increase in revenue for the fourth quarter of 2019, driven by Companion Animal Group (CAG) Diagnostics recurring revenue and growth in the Water and Livestock, Poultry and Dairy (LPD) businesses. Earnings per diluted share were $1.04, representing a 6% growth.